Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: Results of a phase II study with biomarker evaluation

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 4, 2008, Pages 717-725

  Fabi, Alessandra ^a   Metro, Giulio ^a   Papaldo, Paola ^a   Mottolese, Marcella ^a   Melucci, Elisa ^a   Carlini, Paolo ^a   Sperduti, Isabella ^a   Russillo, Michelangelo ^a   Gelibter, Alain ^a   Ferretti, Gianluigi ^b   Tomao, Silverio ^a,b   Milella, Michele ^a,b   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Capecitabine; Celecoxib; COX 2; Metastatic breast cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEARTBURN; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LEUKOPENIA; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; PRODRUGS; PYRAZOLES; SOFT TISSUE NEOPLASMS; SULFONAMIDES; SURVIVAL RATE;

EID: 44849110459     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0650-1     Document Type: Article

References (32)

1. G Demonty C Bernard-Marty F Puglisi I Mancini M Piccart 2007 Progress and new standards of care in the management of HER-2 positive breast cancer Eur J Cancer 43 497 509
2. C Abrial M Leheurteur A Cabrespine MA Mouret-Reynier X Durando JP Ferriere F Kwiatkowski F Penault-Llorca H Cure P Chollet 2006 Does survival increase in metastatic breast cancer with recently available anticancer drugs? Oncol Res 15 431 439
3. Y Cao SM Prescott 2002 Many actions of cyclooxygenase-2 in cellular dynamics and in cancer J Cell Physiol 190 279 286
4. A Ristimaki A Sivula J Lundin M Lundin T Salminen C Haglund H Joensuu J Isola 2002 Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer Cancer Res 62 632 635
5. GS Ranger V Thomas A Jewell K Mokbel 2004 Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer Anticancer Res 24 2349 2351
6. B Arun H Zhang NQ Mirza 2001 Growth inhibition of breast cancer cells by celecoxib Breast Cancer Res Treat 69 234a
7. GA Alshafie HM Abou-Issa K Seibert RE Harris 2000 Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a ratmammary tumor model Oncol Rep 7 1377 1381
8. T Hida K Kozaki H O Ito Miyaishi Y Tatematsu T Suzuki K Matsuo T Sugiura M Ogawa T Takahashi T Takahashi 2002 Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents Clin Cancer Res 8 2443 2447
9. T Irie M Tsujii S T Tsuji Yoshio S Ishii S Shinzaki S Egawa Y Kakiuchi T Nishida M Yasumaru H Iijima H Murata T Takehara S Kawano N Hayashi 2007 Synergistic antitumor effects of celecoxib with 5 fluorouracil depend on IFN-gamma Int J Cancer 121 878 883
10. M Milella A Gelibter S Di Cosimo E Bria EM Ruggeri P Carlini P Malaguti M Pellicciotta E Terzoli F Cognetti 2004 Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma Cancer 101 133 138
11. CD Blanke NC Mattek TG Deloughery DR Koop 2005 A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer Prostaglandins Other Lipid Mediat 75 169 172
12. E Lin JS Morris GD Ayers 2002 Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity Oncology (Williston Park) 16 suppl 14 31 37
13. EH Lin SA Curley CC Crane B Feig J Skibber M Delcos SR Vadhan J Morris GD Ayers A Ross T Brown MA Rodriguez-Bigas N Janjan 2006 Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29 232 239
14. M Miwa M Ura M Nishida N Sawada T Ishikawa K Mori N Shimma I Umeda H Ishitsuka 1998 Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274 1281
15. JL Blum SE Jones AU Buzdar PM Lo Russo I Kuter C Vogel B Osterwalder HU Burger CS Brown T Griffin 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493
16. JL Blum V Dieras PM Lo Russo J Horton O Rutman A Buzdar B Osterwalder 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768
17. P Reichardt G Von Minckwitz PC Thuss-Patience W Jonat H Kolbl F Janicke DG Kieback W Kuhn AE Schindler S Mohrmann M Kaufmann HJ Luck 2003 Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227 1233
18. P Fumoleau R Largillier C Clippe V Dièras H Orfeuvre T Lesimple S Culine B Audhuy D Serin H Curé E Vuillemin JF Morère F Montestruc Z Mouri M Namer 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542
19. E Bajetta G Procopio L Celio L Gattinoni S Della Torre L Mariani L Catena R Ricotta R Longarini N Zilembo R Buzzoni 2005 Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women J Clin Oncol 23 2155 2161
20. BT Hennessy AM Gauthier LB Michaud G Hortobagyi V Valero 2005 Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 16 1289 1296
21. National Cancer Institute (2007) Common toxicity criteria version 3.0. Available from URL: http://ctep.cancer.gov/forms/CTCAEv3.pdf [accessed June 9, 2007]
22. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214
23. RP A'Hern 2001 Sample size tables for exact single-stage phase II designs Stat Med 20 859 866
24. LW Chow WT Loo M Toi 2005 Current directions for COX-2 inhibition in breast cancer Biomed Pharmacother 59 Suppl 2 281 284
25. MM Bertagnolli CJ Eagle AG Zauber M Redston SD Solomon K Kim J Tang RB Rosenstein J Wittes D Corle TM Hess GM Woloj F Boisserie WF Anderson JL Viner D Bagheri J Burn DC Chung T Dewar TR Foley N Hoffman F Macrae RE Pruitt JR Saltzman B Salzberg T Sylwestrowicz GB Gordon ET Hawk APC Study Investigators 2006 Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 873 884
26. BM Psaty JD Potter 2006 Risks and benefits of celecoxib to prevent recurrent adenomas N Engl J Med 355 950 952
27. JA O'Shaughnessy J Blum V Moiseyenko SE Jones D Miles D Bell R Rosso L Mauriac B Osterwalder HU Burger S Laws 2001 Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 1247 1254
28. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing V Langmuir HS Rugo 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799
29. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
30. YS Yap A Kendall G Walsh U Banerji SR Johnston IE Smith M O'brien 2007 Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer-How low can you go? Breast 16 420 424
31. AT Chan S Ogino CS Fuchs 2007 Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356 2131 2142
32. National Cancer Institute (2007) ClinicalTrials.gov. Available from URL: http://clinicaltrials.gov/ct/show/NCT00305643?order=1 [Accessed June 9, 2007]